Acquisition - Narrative (Details)	Nov. 24, 2021 USD ($) right marketedProduct $ / shares	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Business Acquisition [Line Items]
Contingent consideration		$ 56,885,000	$ 80,477,000
Adamas Pharmaceuticals
Business Acquisition [Line Items]
Number of established marketed products | marketedProduct	2
Cash consideration paid	$ 400,806,000
Contingents vale rights | right	2
Rights per share (in dollars per share) | $ / shares	$ 0.50
Additional cash payments upon milestone achievements minimum	$ 150,000,000
Additional cash payments upon milestone achievements maximum	225,000,000
Contingent consideration	10,300,000
Additional cash payments upon milestone achievements minimum	0
Additional cash payments upon milestone achievements maximum	$ 50,900,000